"At present, our novel coronavirus vaccine research and development has successfully entered phase I and phase II clinical research," according to the relevant person in charge. From the feedback provided by the researchers, the safety is good.
According to Beijing Youth Daily, Kexing holding Biotechnology Co., Ltd. took the lead in developing the novel coronavirus vaccine.
"At present, our novel coronavirus vaccine research and development has successfully entered phase I and phase II clinical research," according to the relevant person in charge. From the feedback provided by the researchers, the safety is good. This has a very good foundation for our further expansion of clinical research. In addition to the smooth progress of clinical research, the vaccine production workshop is also under construction. It is expected that the novel coronavirus vaccine will be put into trial production in July.
Yin Weidong, chairman of Kexing holdings, said: "we have carried out a vaccine test on monkeys. Monkeys are the most similar experimental animals to human beings. It is found that when vaccinated monkeys are attacked by a high concentration of new coronavirus, the viral load gradually decreases. After a week, the virus will not be detected, and there is no pathological change. This is encouraging and exciting The news of endeavour. "
According to relevant people, the current vaccine clinical research is proceeding smoothly, with 144 volunteers in the first phase of clinical vaccination and 600 volunteers in the second phase of clinical vaccination. "Every day, we will have experimental feedback from researchers to track the situation of volunteers and observe whether they have adverse reactions. Now it seems that there is no serious adverse reaction, that is to say, the safety of the vaccine is relatively reliable. Of course, this research is very rigorous, requiring double-blind design and Unblinding, etc., and will also make a registration report to the State Food and drug administration, so as to further promote the development of the novel coronavirus vaccine. "
When will the vaccine be ready for use?
"At present, it is impossible to determine a specific time, but the speed of clinical research has been very fast," said the head of Kexing
Usually, novel coronavirus pneumonia vaccine research is needed in phases one or two and three, especially in three phase, which needs to observe the epidemic cycle. It may take a year or two or three years. However, the research and development of novel coronavirus pneumonia vaccine has been rapidly promoted to the first and two stages. We found the virus in January, and entered the two phase only after 4 months, the speed is very fast.
Vaccine research belongs to an overall action plan, and government departments also give a very large strategic layout and support. " At present, Daxing biomedical park has opened up an industrialization base of nearly 70000 square meters. The whole vaccine production workshop is also under construction 24 hours in full swing, and it is expected to be put into trial production in July, the person in charge said.
The successful research and development of the new coronavirus vaccine will greatly reduce the suffering and even loss of life caused by the virus in the world.
